Semaglutide Weight Management and Cardiovascular Risk Reduction

The safety profile of oral semaglutide 50 mg was generally consistent with the GLP-1 receptor agonist drug class Oral semaglutide 50 mg Placebo (n = 333) (n = 334) n % n % . AEs 307 (91.9) 285 (85.6) • Gastrointestinal adverse events 268 (80.2) 154 (46.2) Serious AEs 32 (9.6) 29 (8.7) AEs leading to drug withdrawal 19 (5.7) 12 (3.6) GLP-1: Glucagon like peptide-1; AE: Adverse event Safety: . Majority of gastrointestinal adverse events were mild or moderate in severity • The majority occurred during dose escalation In the trial, oral semaglutide 50 mg appeared to have a safe and well-tolerated profile.

View entire presentation